[^1]
[^2]
[^3]
| Symbol | RIT2 |
| Full Name |
Ras-Like Without CAAX 2 (Rin) |
| Chromosome |
18q12.3 |
| NCBI Gene |
6014 |
| Ensembl |
ENSG00000152214 |
| OMIM |
609592 |
| UniProt |
Q99578 |
| Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease), [Essential Tremor](/diseases/essential-tremor) |
| Expression |
[Neurons](/entities/neurons) (striatum, substantia nigra, [hippocampus](/brain-regions/hippocampus), cortex) |
RIT2 (Ras-Like Without CAAX 2), also known as Rin (Ras-like in neurons), encodes a neuron-specific small GTPase located on chromosome 18q12.3 that has been consistently identified as a Parkinson's disease (PD) risk gene through multiple large-scale genome-wide association studies (GWAS). RIT2 is a member of the Ras superfamily of GTPases but is unique in lacking the C-terminal CAAX prenylation motif found in classical Ras proteins, resulting in distinct membrane localization and signaling properties.
RIT2 is predominantly expressed in neurons, with particularly high expression in dopaminergic neurons of the substantia nigra — the population selectively vulnerable in PD. Functional studies have revealed roles for RIT2 in dopamine transporter (DAT) trafficking, neuronal survival signaling, and synaptic vesicle dynamics, providing mechanistic links between genetic association and disease pathophysiology.
¶ Gene Structure and Protein Products
The RIT2 gene spans approximately 260 kb on chromosome 18q12.3 and contains 6 exons. The PD-associated GWAS signal maps to a broad region spanning the gene, with the lead SNP (rs12456492) located in the intergenic region near the 5' end, suggesting regulatory effects on gene expression.
The RIT2 protein (217 amino acids) is a monomeric GTPase with characteristic features:
- G domain: Contains the conserved GTP-binding and hydrolysis motifs (G1-G5 boxes), functioning as a molecular switch between active (GTP-bound) and inactive (GDP-bound) states
- Effector domain: Interacts with downstream signaling partners including RAF kinases, RGL (RalGDS-like) proteins, and p38 MAPK
- C-terminal polybasic region: Unlike classical Ras proteins that use a CAAX motif for prenylation, RIT2 uses a polybasic/palmitoylation mechanism for membrane association, allowing more dynamic membrane cycling
- Switch I/II regions: Conformational switches that change upon GTP binding, controlling effector interactions
RIT2 cycles between active and inactive states:
- Activation: Guanine nucleotide exchange factors (GEFs) promote GTP loading
- Inactivation: GTPase-activating proteins (GAPs) stimulate intrinsic GTP hydrolysis
- The relatively slow intrinsic GTP hydrolysis rate of RIT2 results in prolonged signaling activity compared to classical Ras
A critical function linking RIT2 to PD pathophysiology is its regulation of dopamine transporter (DAT/SLC6A3) membrane dynamics:
- RIT2 directly interacts with DAT and regulates its endocytic recycling at dopaminergic neuron terminals
- GTP-bound (active) RIT2 promotes DAT surface expression by inhibiting PKC-stimulated DAT internalization
- RIT2 knockdown increases DAT endocytosis, reducing dopamine reuptake capacity
- This function links RIT2 to dopamine homeostasis in the striatum, where precise DAT regulation is essential for normal motor function
RIT2 activates pro-survival pathways in neurons:
- ERK/MAPK pathway: RIT2 activates ERK1/2 signaling through B-Raf, promoting neuronal survival and differentiation
- p38 MAPK pathway: Under stress conditions, RIT2 activates p38 MAPK, mediating stress-responsive gene expression
- AKT/PI3K signaling: RIT2 contributes to AKT-mediated survival signaling, particularly important for dopaminergic neuron resilience
- NGF signaling: RIT2 modulates nerve growth factor (NGF) and BDNF signaling through TrkA/TrkB receptors
RIT2 participates in synaptic function:
- Localizes to synaptic terminals in dopaminergic neurons
- Interacts with synaptic vesicle-associated proteins
- Modulates vesicle recycling and neurotransmitter release
- May regulate the synaptic vesicle endocytosis machinery through interaction with calmodulin
- Promotes neurite outgrowth through ERK and p38 MAPK signaling
- Required for proper neuronal differentiation in the developing brain
- Expressed early in neuronal differentiation and maintained in mature neurons
RIT2 is one of the most robustly replicated PD risk genes from GWAS:
- GWAS discovery: The RIT2 locus was first identified as a PD risk locus in a meta-analysis of over 7,000 PD cases, with rs12456492 reaching genome-wide significance (p = 7.0 × 10⁻⁸)
- Replication: Subsequently replicated in multiple independent cohorts across European and Asian populations, with consistent effect sizes (OR ~1.1–1.15)
- Expression changes: RIT2 mRNA levels are significantly reduced in the substantia nigra of PD patients compared to age-matched controls
- eQTL evidence: PD risk alleles at the RIT2 locus are associated with reduced RIT2 expression in brain tissue, suggesting a loss-of-function mechanism
- Functional links: RIT2 deficiency impairs DAT trafficking, disrupting dopamine homeostasis — a core pathological feature of PD
- Alpha-synuclein interaction: RIT2 modulates the cellular response to alpha-synuclein overexpression; reduced RIT2 may enhance synuclein-mediated toxicity
- LRRK2 pathway: RIT2 and LRRK2 may converge on vesicle trafficking pathways, with both affecting endosomal dynamics in dopaminergic neurons
- RIT2 variants have been associated with essential tremor risk in some studies
- The neuronal specificity of RIT2 and its role in synaptic transmission may explain tremor phenotypes
- Preliminary evidence suggests RIT2 variants may contribute to restless legs syndrome risk
- Dopaminergic dysfunction is central to restless legs syndrome pathophysiology, consistent with RIT2's DAT regulatory function
RIT2 is exclusively expressed in neurons with a distinctive regional pattern:
- Substantia nigra: High expression in dopaminergic neurons of the pars compacta (A9 population)
- Ventral tegmental area: Moderate expression in A10 dopaminergic neurons
- Striatum: Expression in medium spiny neurons (putamen > caudate)
- Hippocampus: CA1–CA3 pyramidal neurons and dentate gyrus
- Cerebral cortex: Layers III and V pyramidal neurons
- Cerebellum: Purkinje cells show moderate expression
The high expression in substantia nigra dopaminergic neurons — the population selectively lost in PD — provides strong biological plausibility for RIT2's role in PD pathogenesis.
- RIT2 expression begins during early neuronal differentiation (embryonic day 12 in mice)
- Expression increases during postnatal development and reaches peak levels in adulthood
- Expression declines with normal aging, potentially contributing to age-related dopaminergic vulnerability
- Activity-dependent regulation through CREB and MEF2 transcription factors
- Epigenetic regulation: DNA methylation at the RIT2 promoter increases with age and in PD brain
- Post-transcriptional regulation by miR-127-3p, which targets RIT2 mRNA
RIT2 biology suggests several therapeutic strategies for PD:
- RIT2 expression enhancement: Small molecules or gene therapy to restore reduced RIT2 expression in dopaminergic neurons
- DAT trafficking modulators: Compounds that mimic RIT2's effect on DAT surface expression, maintaining dopamine reuptake capacity
- GTPase activators: Small molecules that stabilize the GTP-bound active form of RIT2
- Downstream pathway activation: Targeting ERK or AKT pathways activated by RIT2 to promote dopaminergic neuron survival
- AAV-mediated RIT2 overexpression in the substantia nigra/striatum
- CRISPR-based approaches to modify PD risk variants at the RIT2 locus
- Antisense oligonucleotide targeting of RIT2-suppressive miRNAs
- Plasma or CSF RIT2 protein levels as potential PD biomarkers
- RIT2 promoter methylation as an epigenetic marker of disease state
- Pankratz et al., Meta-analysis of Parkinson's disease identifies a novel locus, RIT2 (2012)
- Navaroli et al., The plasma membrane-associated GTPase Rin interacts with the dopamine transporter (2011)
- Nalls et al., Large-scale meta-analysis of genome-wide association data identifies PD risk loci including RIT2 (2014)